Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Fuji
Chubb
Accenture
Harvard Business School
UBS

Generated: April 21, 2019

DrugPatentWatch Database Preview

STALEVO 125 Drug Profile

« Back to Dashboard

When do Stalevo 125 patents expire, and what generic alternatives are available?

Stalevo 125 is a drug marketed by Orion Pharma and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-eight patent family members in forty-one countries.

The generic ingredient in STALEVO 125 is carbidopa; entacapone; levodopa. There are eighteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the carbidopa; entacapone; levodopa profile page.

Summary for STALEVO 125
Drug patent expirations by year for STALEVO 125
Synonyms for STALEVO 125
745835-09-0
Carbidopa mixture with Entacapone and Levodopa
Carbidopa, levodopa, and entacapone
Carbidopa/levodopa/entacapone
DTXSID10225560
ELC200
L-Tyrosine, 3-hydroxy-, mixt. with (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide and (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
SCHEMBL3808214
Stalevo 100
Stalevo 200
Stalevo 50
Stalevo 75

US Patents and Regulatory Information for STALEVO 125

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orion Pharma STALEVO 125 carbidopa; entacapone; levodopa TABLET;ORAL 021485-006 Aug 29, 2008 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Orion Pharma STALEVO 125 carbidopa; entacapone; levodopa TABLET;ORAL 021485-006 Aug 29, 2008 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for STALEVO 125

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Orion Pharma STALEVO 125 carbidopa; entacapone; levodopa TABLET;ORAL 021485-006 Aug 29, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Orion Pharma STALEVO 125 carbidopa; entacapone; levodopa TABLET;ORAL 021485-006 Aug 29, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Orion Pharma STALEVO 125 carbidopa; entacapone; levodopa TABLET;ORAL 021485-006 Aug 29, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for STALEVO 125
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 18.75 mg/75 mg/200 mg and 31.25 mg/125 mg/200 mg ➤ Subscribe ➤ Try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Johnson and Johnson
Daiichi Sankyo
QuintilesIMS
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.